189 related articles for article (PubMed ID: 1457929)
1. Low calcium peritoneal dialysis solution. Effects on calcium metabolism and bone disease in CAPD patients.
Carozzi S; Nasini MG; Schelotto C; Caviglia PM; Santoni O; Pietrucci A
ASAIO J; 1992; 38(3):M593-5. PubMed ID: 1457929
[TBL] [Abstract][Full Text] [Related]
2. Low Ca2+ dialysate. Effects on bone metabolism in the course of paired filtration dialysis.
Carozzi S; Nasini MG; Pietrucci A; Costa M; Mantero R
ASAIO J; 1994; 40(3):M683-5. PubMed ID: 8555601
[TBL] [Abstract][Full Text] [Related]
3. Low- and high-turnover bone disease in continuous ambulatory peritoneal dialysis: effects of low-Ca2+ peritoneal dialysis solution.
Carozzi S; Nasini MG; Santoni O; Pietrucci A
Perit Dial Int; 1993; 13 Suppl 2():S473-5. PubMed ID: 8399644
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
Weinreich T; Ritz E; Passlick-Deetjen J
Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
[TBL] [Abstract][Full Text] [Related]
6. Reversibility of parathyroid gland suppression in CAPD patients with low i-PTH levels.
Montenegro J; Saracho R; González O; Moina I; Martínez I
Clin Nephrol; 1997 Dec; 48(6):359-63. PubMed ID: 9438094
[TBL] [Abstract][Full Text] [Related]
7. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder.
Cheng IK; Lu HB; Chan CY; Cheng SW; Robinson JD; Tam SC; Lo WK; Cheung WC
Clin Nephrol; 1993 Aug; 40(2):100-5. PubMed ID: 8222365
[TBL] [Abstract][Full Text] [Related]
8. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
Bro S; Brandi L; Olgaard K
Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing 2.5 mEq/L calcium dialysate and calcitriol to 3.5 mEq/L calcium dialysate in patients on peritoneal dialysis.
Banalagay E; Bernardini J; Holley J; Chen T; Piraino B
Adv Perit Dial; 1993; 9():280-3. PubMed ID: 8105943
[TBL] [Abstract][Full Text] [Related]
10. Effect of CAPD and hemodialysis on parathyroid function.
Malberti F; Corradi B; Imbasciati E
Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
[TBL] [Abstract][Full Text] [Related]
11. CAPD with low calcium dialysate and calcium carbonate: results of a 24-week study.
Honkanen E; Kala AR; Grönhagen-Riska C; Ikäheimo R
Adv Perit Dial; 1992; 8():356-61. PubMed ID: 1361822
[TBL] [Abstract][Full Text] [Related]
12. [The impact of low calcium dialysate (1.25 mmol/l; LCD) on bone metabolism in CAPD patients].
Terawaki H; Kasai K; Kawaguchi Y; Kobayashi H; Hirano K; Ohtsuka Y; Hosoya T
Nihon Jinzo Gakkai Shi; 1998 May; 40(4):252-7. PubMed ID: 9654908
[TBL] [Abstract][Full Text] [Related]
13. High-dose oral calcitriol and zero calcium peritoneal solutions in CAPD patients with refractory secondary hyperparathyroidism.
Malberti F; Scanziani R; Corradi B; Dozio B; Bonforte G; Imbasciati E; Surian M
Nephrol Dial Transplant; 1994; 9(12):1813-5. PubMed ID: 7708273
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis.
Brandi L; Nielsen PK; Bro S; Daugaard H; Olgaard K
J Intern Med; 1998 Aug; 244(2):121-31. PubMed ID: 10095798
[TBL] [Abstract][Full Text] [Related]
15. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
Yaginuma T; Yamamoto H
Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
[TBL] [Abstract][Full Text] [Related]
16. Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD.
Passlick J; Wilhelm M; Busch T; Grabensee B; Ohnesorge FK
Clin Nephrol; 1989 Aug; 32(2):96-100. PubMed ID: 2766587
[TBL] [Abstract][Full Text] [Related]
17. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium.
Spasovski G; Gelev S; Masin-Spasovska J; Selim G; Sikole A; Vanholder R
Bone; 2007 Oct; 41(4):698-703. PubMed ID: 17643363
[TBL] [Abstract][Full Text] [Related]
18. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study.
Sánchez C; López-Barea F; Sánchez-Cabezudo J; Bajo A; Mate A; Martínez E; Selgas R;
Nephrol Dial Transplant; 2004 Jun; 19(6):1587-93. PubMed ID: 15069173
[TBL] [Abstract][Full Text] [Related]
19. Low calcium (1.25 mmol/L) dialysate can normalize relative hypoparathyroidism in CAPD patients with low bone turnover.
Shigematsu T; Kawaguchi Y; Kubo H; Nakayama M; Kato N; Yamamoto H; Osaka N; Hayakawa H; Ogawa A; Sakai O
Adv Perit Dial; 1996; 12():250-6. PubMed ID: 8865914
[TBL] [Abstract][Full Text] [Related]
20. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
